U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula I.Na
Molecular Weight 153.8959
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of SODIUM IODIDE I-131

SMILES

[Na+].[131I-]

InChI

InChIKey=FVAUCKIRQBBSSJ-LAIFMVDKSA-M
InChI=1S/HI.Na/h1H;/q;+1/p-1/i1+4;

HIDE SMILES / InChI

Molecular Formula Na
Molecular Weight 22.9898
Charge 1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula HI
Molecular Weight 131.9141
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Iodide I-131 (as Sodium iodide I-131) is a radioisotopic drug used for the treatment and palliation of thyroid malignancy. Therapeutic solutions of Sodium Iodide-131 are indicated for the treatment of hyperthyroidism and thyroid carcinomas that take up iodine. Palliative effects may be observed in patients with advanced thyroid malignancy if the metastatic lesions take up iodine. It is also indicated for use in performance of the radioactive iodide (RAI) uptake test to evaluate thyroid function. Taken orally, sodium iodide I-131 is rapidly absorbed and distributed within the extracellular fluid of the body. The iodide is concentrated in the thyroid via the sodium/iodide symporter, and subsequently oxidized to iodine. The destruction of thyroidal tissue is achieved by the beta emission of sodium iodide I-131.

Originator

Curator's Comment: Iodine-131 (131I) is an important radioisotope of iodine discovered by Glenn Seaborg and John Livingood in 1938 at the University of California, Berkeley.

Approval Year

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
SODIUM IODIDE I 131

Approved Use

Sodium Iodide I 131 is indicated for the treatment of hyperthyroidism and thyroid carcinomas that take up iodide. Palliative effects may be observed in patients with advanced thyroid malignancy if the metastatic lesions take up iodide.

Launch Date

1971
Primary
SODIUM IODIDE I 131

Approved Use

Sodium Iodide I 131 is indicated for the treatment of hyperthyroidism and thyroid carcinomas that take up iodide. Palliative effects may be observed in patients with advanced thyroid malignancy if the metastatic lesions take up iodide.

Launch Date

1971

Sample Use Guides

The recommended dosage for orally administered Sodium Iodide I 131 Capsule USP is based on the thyroid gland uptake as well as the size of the gland. Thyroidal uptake and size should be determined by the physician prior to treatment and may be useful in calculating the therapeutic dose to be administered to the individual patient. Recommended dosages of orally administered Sodium Iodide I-131 are: Disease therapy: Antihyperthyroid Therapy: Oral dose of 148 to 370 megabecquerels (4 to 10 millicuries). Toxic nodular goiters and other serious thyroid conditions may require larger dosages. Antineoplastic – Ablation of normal thyroid tissue: Initial oral dose of 1.1 to 3.7 gigabecquerels (30 to 100 millicuries).Subsequent ablation of metastases with oral dose of 3.7 to 7.4 gigabecquerels (100 to 200 millicuries).
Route of Administration: Oral
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:48:34 GMT 2023
Edited
by admin
on Fri Dec 15 15:48:34 GMT 2023
Record UNII
29VCO8ACHH
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
SODIUM IODIDE I-131
ORANGE BOOK  
Common Name English
sodium iodide (¹³¹I) [INN]
Common Name English
THERIODIDE-131
Brand Name English
SODIUM IODIDE I131
Common Name English
SODIUM IODIDE (131I)
INN  
INN  
Official Name English
RADIOCAPS-131
Brand Name English
IODINE (131I) SODIUM
Common Name English
SODIUM IODIDE I 131 [USAN]
Common Name English
SODIUM IODIDE I 131
HSDB   MI   USAN   USP  
USAN  
Official Name English
SODIUM IODIDE (131 I)
WHO-DD  
Common Name English
SODIUM IODIDE-131
Brand Name English
TRACERVIAL
Brand Name English
SODIUM IODIDE,I-131 [VANDF]
Common Name English
SODIUM IODIDE, I-131
Common Name English
RADIOCAPS
Brand Name English
TRACERVIAL-131
Brand Name English
THERIODIDE
Brand Name English
SODIUM IODIDE I 131 [MI]
Common Name English
SODIUM IODIDE I-131 [ORANGE BOOK]
Common Name English
ORIODIDE
Brand Name English
SODIUM IODIDE I 131 [HSDB]
Common Name English
SODIUM IODIDE I 131 [USP IMPURITY]
Common Name English
IODOTOPE
Brand Name English
Sodium iodide (131 i) [WHO-DD]
Common Name English
Classification Tree Code System Code
NDF-RT N0000175872
Created by admin on Fri Dec 15 15:48:34 GMT 2023 , Edited by admin on Fri Dec 15 15:48:34 GMT 2023
WHO-VATC QV10XA01
Created by admin on Fri Dec 15 15:48:34 GMT 2023 , Edited by admin on Fri Dec 15 15:48:34 GMT 2023
NCI_THESAURUS C2125
Created by admin on Fri Dec 15 15:48:34 GMT 2023 , Edited by admin on Fri Dec 15 15:48:34 GMT 2023
WHO-VATC QV09FX03
Created by admin on Fri Dec 15 15:48:34 GMT 2023 , Edited by admin on Fri Dec 15 15:48:34 GMT 2023
WHO-ATC V10XA01
Created by admin on Fri Dec 15 15:48:34 GMT 2023 , Edited by admin on Fri Dec 15 15:48:34 GMT 2023
WHO-ATC V09FX03
Created by admin on Fri Dec 15 15:48:34 GMT 2023 , Edited by admin on Fri Dec 15 15:48:34 GMT 2023
Code System Code Type Description
DRUG CENTRAL
5038
Created by admin on Fri Dec 15 15:48:34 GMT 2023 , Edited by admin on Fri Dec 15 15:48:34 GMT 2023
PRIMARY
DRUG BANK
DB09293
Created by admin on Fri Dec 15 15:48:34 GMT 2023 , Edited by admin on Fri Dec 15 15:48:34 GMT 2023
PRIMARY
LACTMED
Sodium Iodide I 131
Created by admin on Fri Dec 15 15:48:34 GMT 2023 , Edited by admin on Fri Dec 15 15:48:34 GMT 2023
PRIMARY
NCI_THESAURUS
C47725
Created by admin on Fri Dec 15 15:48:34 GMT 2023 , Edited by admin on Fri Dec 15 15:48:34 GMT 2023
PRIMARY
MERCK INDEX
m10035
Created by admin on Fri Dec 15 15:48:34 GMT 2023 , Edited by admin on Fri Dec 15 15:48:34 GMT 2023
PRIMARY Merck Index
FDA UNII
29VCO8ACHH
Created by admin on Fri Dec 15 15:48:34 GMT 2023 , Edited by admin on Fri Dec 15 15:48:34 GMT 2023
PRIMARY
DAILYMED
29VCO8ACHH
Created by admin on Fri Dec 15 15:48:34 GMT 2023 , Edited by admin on Fri Dec 15 15:48:34 GMT 2023
PRIMARY
PUBCHEM
71368
Created by admin on Fri Dec 15 15:48:34 GMT 2023 , Edited by admin on Fri Dec 15 15:48:34 GMT 2023
PRIMARY
HSDB
7790-26-3
Created by admin on Fri Dec 15 15:48:34 GMT 2023 , Edited by admin on Fri Dec 15 15:48:34 GMT 2023
PRIMARY
EPA CompTox
DTXSID701014487
Created by admin on Fri Dec 15 15:48:34 GMT 2023 , Edited by admin on Fri Dec 15 15:48:34 GMT 2023
PRIMARY
SMS_ID
100000093019
Created by admin on Fri Dec 15 15:48:34 GMT 2023 , Edited by admin on Fri Dec 15 15:48:34 GMT 2023
PRIMARY
EVMPD
SUB12294MIG
Created by admin on Fri Dec 15 15:48:34 GMT 2023 , Edited by admin on Fri Dec 15 15:48:34 GMT 2023
PRIMARY
RXCUI
91535
Created by admin on Fri Dec 15 15:48:34 GMT 2023 , Edited by admin on Fri Dec 15 15:48:34 GMT 2023
PRIMARY RxNorm
ChEMBL
CHEMBL1644695
Created by admin on Fri Dec 15 15:48:34 GMT 2023 , Edited by admin on Fri Dec 15 15:48:34 GMT 2023
PRIMARY
EVMPD
SUB127361
Created by admin on Fri Dec 15 15:48:34 GMT 2023 , Edited by admin on Fri Dec 15 15:48:34 GMT 2023
ALTERNATIVE
CAS
7790-26-3
Created by admin on Fri Dec 15 15:48:34 GMT 2023 , Edited by admin on Fri Dec 15 15:48:34 GMT 2023
PRIMARY
EVMPD
SUB127360
Created by admin on Fri Dec 15 15:48:34 GMT 2023 , Edited by admin on Fri Dec 15 15:48:34 GMT 2023
ALTERNATIVE
INN
279
Created by admin on Fri Dec 15 15:48:34 GMT 2023 , Edited by admin on Fri Dec 15 15:48:34 GMT 2023
PRIMARY
Related Record Type Details
ACTIVE MOIETY